Proteq West Nile

RSS

West Nile fever vaccine (live recombinant)

Authorised
This medicine is authorised for use in the European Union.

Overview

Proteq West Nile is a veterinary vaccine that contains West Nile recombinant canarypox virus (vCP2017). It is available as a suspension for injection.

Proteq West Nile is used to protect horses from 5 months of age against West Nile disease. West Nile disease is a mosquito-borne viral disease that can cause encephalitis (inflammation of the brain) and meningitis (inflammation of the lining of the brain and spinal cord).The vaccine is used to reduce the number of horses with the West Nile virus in their blood (viraemia) or with clinical signs of the disease.

This EPAR was last updated on 15/02/2021

Authorisation details

Product details
Name
Proteq West Nile
Agency product number
EMEA/V/C/002005
Active substance
West Nile recombinant canarypox virus (vCP2017 virus)
International non-proprietary name (INN) or common name
West Nile fever vaccine (live recombinant)
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI05AX
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
05/08/2011
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Product information

14/08/2020 Proteq West Nile - EMEA/V/C/002005 - IG/1279

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for equidae

  • Horse

Therapeutic indication

Active immunisation of horses from five months of age against West Nile disease by reducing the number of viraemic horses. If clinical signs are present, their duration and severity are reduced.

Assessment history

How useful was this page?

Add your rating